Related Experiment Video

Updated: Aug 16, 2025

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.6K

Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours

Yuehua Li1, Chengjiang Wei1, Wei Wang1

  • 1Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.

The Journal of Pathology. Clinical Research
|December 19, 2022
PubMed

Insights

Tropomyosin receptor kinase B (TrkB) is crucial for neural development. Its abnormal activation drives neurogenic tumors, but targeted therapies like TrkB inhibitors show promise.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cancer therapeutics

Background:

  • Tropomyosin receptor kinase B (TrkB), encoded by the NTRK2 gene, is vital for neural development.
  • Aberrant TrkB activation via NTRK2 overexpression or fusion promotes neurogenic tumor initiation and progression.
  • This abnormal signaling contributes to therapeutic resistance in various neurogenic tumors.

Purpose of the Study:

  • To review the gene structure and biological function of TrkB.
  • To elucidate the mechanisms of abnormal TrkB activation in neurogenic tumors.
  • To summarize current targeted therapies for TrkB-driven neurogenic tumors.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of gene structure and protein function.
  • Examination of therapeutic strategies targeting TrkB.

Main Results:

  • NTRK2 alterations lead to oncogenic TrkB signaling in neurogenic tumors.
  • Targeted therapies, including selective TrkB and pan-TRK inhibitors, are under investigation.
  • These therapies aim to overcome treatment resistance mediated by TrkB.

Conclusions:

  • TrkB plays a critical role in the pathogenesis of neurogenic tumors.
  • Targeted inhibition of TrkB represents a promising therapeutic strategy.
  • Further research into TrkB-targeted therapies is warranted for neurogenic malignancies.
Keywords:
NTRKTrkBabnormal activationgene fusionneurogenic tumourstargeted therapytyrosine kinase

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.2K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.9K

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
79.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.5K